Heart failure (HF) is one of the leading causes of hospitalization and death worldwide. Remote patient monitoring and digital therapeutics could help reduce the consumption of care for these patients (hospitalizations, emergency room visits) and optimize their management (education, medication optimization). This randomized study aims to evaluate the effects of the Continuum software solution in patients with heart failure, whether or not they are followed in specialized clinics. Heart failure is one of the main causes of hospitalization and death in the world. Evidence suggests that remote patient monitoring (RPM) and digital therapeutics (DTX solutions) can help improve care consumption (i.e. hospitalizations, emergency visits) and also support health care professionals to improve care (i.e. symptoms management, drug optimization). This randomised study aims to evaluate the effects of these two software solutions in the context of specialized HF clinics (HFC) and primary health care on health care consumption and clinical events.
According to Canadian recommendations, patients recently diagnosed with heart failure or with a recent hospitalization should have a medical follow-up every two to four weeks in order to optimize their treatment and quickly stabilize their condition. However, despite a network of specialized heart failure clinics in the province of Quebec, access to this service is still a challenge because of limited human resources and unequal geographic distribution. Only the most severely ill and unstable patients are followed in these clinics. The Continuum project combines a remote patient monitoring solution with therapeutic interventions driven by a software to manage heart failure (also called digital therapeutics (DTx)). The patient can send her/his clinical data to the healthcare professional using a mobile application. Healthcare professionals receive not only these data in realtime with potential alerts but also a summarized report of these data and suggested therapeutic interventions. Our hypotheses are that the Continuum solution, by combining RPM and DTx will 1) improve the workflow and the care trajectory of patients in heart failure clinics resulting in a reduction of cost per patient followed and 2) accelerate drug optimization so they can fully benefit from the recommended therapies for their specific condition. The general objective of this project is to assess in outpatients the effectiveness of the Continuum solution to reduce healthcare costs and to support medication optimization over a period of 12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
175
Combination of a mobile application (with remote monitoring) and digital therapeutics
No mobile application or digital therapeutics are used
Combination of a mobile application (without remote monitoring) and digital therapeutics
CRCHUM
Montreal, Quebec, Canada
CLIC IN ONLY: care consumption
Cost analysis on number of hospital (planned or unplanned) ambulatory visits, emergency visits, consultations and hospitalizations
Time frame: 12 weeks
CLIC OUT ONLY: Change in guideline-directed medical therapy by classes
Change in guideline-directed medical Therapy optimization between groups before and after intervention by medication classes.
Time frame: 12 weeks
CLIC OUT ONLY: Change in guideline-directed medical therapy by dose
Change in guideline-Directed Medical Therapy optimization between groups before and after intervention by medication doses.
Time frame: 12 weeks
CLIC OUT ONLY: Care consumption
Cost analysis on number of hospital (planned or unplanned) ambulatory visits, emergency visits, consultations and hospitalizations during intervention
Time frame: 12 weeks
CLIC IN ONLY: Change in guideline-directed medical therapy by classes
Compare guideline-Directed Medical Therapy optimization between groups before and after intervention by medication classes
Time frame: 12 weeks
CLIC IN ONLY: Change in guideline-directed medical therapy by doses
Compare guideline-Directed Medical Therapy optimization between groups before and after intervention by medication doses
Time frame: 12 weeks
MACE and other clinical events
Differences before-after between groups in number of main clinical events including unplanned appointments, emergency consults, all-cause or heart-failure hospitalizations, deaths
Time frame: 12 weeks
CLIC IN ONLY: Quality of life assessment (QoL) with the Kansas City Cardiomyopathy Questionnaire
Differences in score before and after
Time frame: 12 weeks
Quality of life assessment (QoL) with the EQ-5D-5L EuroQOL instrument
Differences in score before and after
Time frame: 12 weeks
New York Heart Association class
A reduction of at least one class in New York Heart Association (NYHA) scale
Time frame: 12 weeks
NTproBNP
Reduction in NTproBNP greater than 30%
Time frame: 12 weeks
Pharmacological profile
Percentage of recommended heart failure drugs prescribed
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.